ENSURE Non-invasive follow-up of urinary tract cancers
- Coordinator
- Nova Id Fct - Associacao Para a Inovacao E Desenvolvimento Da Fct, Portugal
- Runs
- 1 July 2022 to 30 June 2024
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- European Research Council grant
- Grant agreement
- 101069405
What the project is doing
In the project's own words, from its summary on CORDIS.
Bladder cancer is the most common malignancy of the urinary tract with 573,000 new cases and 213,000 deaths in 2020 worldwide and affecting more men than women in a 4:1 ratio. Bladder cancer has the highest lifetime treatment costs per patient of all cancers, which is mainly attributed to the intensive follow-up procedures of patients after diagnostics and surgery. Follow-up is made recurring to extremely invasive and low-patient compliant tests.
ENSURE aims to validate the technological and business feasibility of the electronic nose technology developed in the ERC Starting Grant SCENT by establishing the proof-of-concept for the non-invasive follow-up of bladder cancer patients. To accomplish this, we will approach the project from both Technical and Business perspectives, with a perfect synergy between the research and business teams, and a close contact with clinical collaborators and stakeholders.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Nova Id Fct - Associacao Para a Inovacao E Desenvolvimento Da Fct | Caparica | Portugal | Coordinator |
| Day One Societa a Responsabilita Limitata | Roma Rm | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI